^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Excerpt:
The study included 123 patients diagnosed with MDS per the WHO 2008/2016 classification; 98 of them were treated with AZA…The median mRNA levels of RRM1 were 4.2 times higher in non-responders (p=0.019) in comparison to responders….MDS patients with low RRM1 levels had a better response to AZA-treatment.
DOI:
10.1182/blood-2019-126426